Exclusive Japanese Patent
– Autologous NK Immune Cell Therapy for Cancer
In partnership with medical institutions, we provide GTP (Good Tissue Practice) grade cell preparation facilities approved by Taiwan’s Ministry of Health and Welfare under the “Regulation Governing the Application of Specific Medical Examination Technique and Medical Device (RSMT) .”
NK Immune Cell Therapy
- Officially Approved NK Cell Therapy : Certified NK Cell Therapy by Government Authorization.
- In Collaboration With: Shuang Ho Hospital, Ministry of Health and Welfare.
- Applicable Treatments: Lung, Colorectal, Head & Neck, Breast, Ovarian, Cervical, and Pancreatic Cancers.
NK Immune Cell Therapy Complies with RSMT,
MOHW No. 109DOMA075
Cell Processing Unit Complies with GTP , TFDA
No. 衛部醫字第1141661325號
Treatment Plan:
- 50 cc blood draw followed by cell infusion
- Each cultivation cycle requires 3 weeks
- Six infusions in total
- The full course spans approximately 18 weeks
真實世界治療數據 RWD＞40,000人
成功案例之癌別類型
NK Cell Technology Licensed by Leading Japanese Immunology Expert
1. 1,500-fold expansion of cell numbers
2. Over 6 billion NK cells generated
3. NK cell purity above 80%
4. Cytotoxic activity surpassing 70%
The treatment data above are based on authentic clinical cases from Supercell Biotechnology Corporation
Culturing for 21 days produces CD56brightCD16+ NK cells endowed with both immunoregulatory and cytotoxic properties against cancer.
